The present invention relates to a process for the preparation of bortezomib (Formula I) and its intermediates.

The invention relates to crystalline barium salt of (S)-omeprazole which is (S)-5-methoxy-2-[[(4-methoxy-35-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole. The invention also relates to processes for preparing crystalline barium salt of (S)-omeprazole and pharmaceutical compositions that include the crystalline barium salt of (S)-omeprazole so prepared.

The present invention relates to the N-Methylformamide solvate of dasatinib a process for its preparation. Formula (I)

The present invention relates to an improved process for the preparation of atazanavir bisulfate, an inhibitor of retroviral aspartate protease. The process of the present invention comprises conversion of 1,1-dimethylethyl[(2S,3R)-4-chloro-3-hydroxy- -phenylbutan-2-yl]carbamate (Formula II) into 1-[4-(pyridine-2-yl)-phenyl]-4(S)-5 hydroxy-2-N-tert-butoxycarbonylamino-5(S)-N-(N-methoxycarbonyl-(L)-tert- leucyl)amino-6-phenyl-2-azahexane (Formula VII) without isolating intermediate compounds form...

The present invention provides sorafenib ethane sulphonate process for its preparation pharmaceutical composition comprising sorafenib ethane sulphonate and its use for the treatment of cancer. Formula (III).

The present invention provides a process for the preparation of sorafenib tosylate comprising contacting sorafenib free base with p-toluenesulphonic acid in water.

The present invention provides processes and intermediates for preparing cinacalcet base and pharmaceutically acceptable salts thereof.

The present invention relates to processes for the preparation of erlotinib hydrochloride Form A and erlotinib hydrochloride Form B. (I).

The present invention provides an efficient process for the purification of pioglitazone of Formula (I). It provides an improved purification for the preparation of pioglitazone substantially free of the DHP impurity of Formula (II).